Istaraatiijiyada daawaynta ee myelofibrosis aasaasiga ah (PMF) waxay ku salaysan tahay shaandhaynta khatarta ah.Sababo la xiriira noocyada kala duwan ee muuqaalada kiliinikada iyo arrimaha wax looga qabanayo bukaanada PMF, xeeladaha daawaynta waxay u baahan yihiin inay tixgeliyaan cudurka bukaanka iyo baahiyaha caafimaad.Daawaynta bilawga ah ee ruxolitinib (Jakavi/Jakafi) ee bukaanada leh beeryarada weyn waxay muujisay hoos u dhac weyn oo beeryarada waxayna ka madax banaan tahay xaalada isbeddelka darawalka.Baaxadda weyn ee dhimista beeryarada waxay soo jeedinaysaa saadaal wanaagsan.Bukaannada halista ugu yar ee aan lahayn cudur kiliinik ahaan muhiim ah, waa la arki karaa ama la geli karaa tijaabooyin bukaan-socod, iyadoo qiimeyn lagu soo celinayo 3-6 bilood kasta.Ruxolitinib(Jakavi/Jakafi) daawaynta mukhaadaraadka waxaa lagu bilaabi karaa bukaan-hooseeya ama kuwa dhexdhexaadka ah-1 bukaanada qaba splenomegaly iyo/ama cudur bukaan-socod, marka loo eego tilmaamaha daaweynta NCCN.
Khatar-dhexe-2 ama bukaannada khatarta sare leh, HSCT-da allogeneic ayaa la door bidaa.Haddii aan la heli karin ku-tallaalidda, ruxolitinib (Jakavi/Jakafi) ayaa lagula talinayaa inay noqoto xulashada daawaynta safka hore ama in la galo tijaabooyin caafimaad.Ruxolitinib (Jakavi/Jakafi) waa dawada kaliya ee hadda la ansixiyey aduunka oo dhan taas oo beegsata dariiqa firfircoon ee JAK/STAT, pathogenesis ee MF.Laba daraasadood oo lagu daabacay Jariidada New England iyo Joornaalka Leukemia & Lymphoma waxay soo jeedinayaan in ruxolitinib (Jakavi / Jakafi) ay si weyn u yareyn karto cudurka oo ay wanaajiso tayada nolosha bukaanka PMF.Khatarta dhexdhexaadka ah-2 iyo bukaannada MF ee khatarta sare leh, ruxolitinib (Jakavi / Jakafi) waxay awoodeen inay yareeyaan beeryarada, hagaajinta cudurka, hagaajinta badbaadada, iyo hagaajinta pathology dhuuxa lafaha, oo la kulma ujeedooyinka asaasiga ah ee maaraynta cudurka.
PMF waxay leedahay suurtogalnimada dhacdooyinka sanadlaha ah ee 0.5-1.5/100,000 waxayna leedahay saadaasha ugu xun ee dhammaan MPNs.PMF waxaa lagu gartaa myelofibrosis iyo hematopoiesis dheeraad ah.PMF, fibroblasts dhuuxa lafta kama soo bixin clones aan caadi ahayn.Qiyaastii saddex-meelood meel bukaannada qaba PMF ma laha wax calaamado ah waqtiga cudurka.Cabashooyinka waxaa ka mid ah daal weyn, dhiig-yaraan, calool xanuun, shuban ay sabab u tahay dheregnaanta hore ama splenomegaly, dhiig-baxa, miisaan lumis, iyo bararka durugsan.Ruxolitinib(Jakavi/Jakafi) ayaa la ansixiyay Ogosto 2012 daawaynta dhexe ama khatarta sare ee myelofibrosis, oo ay ku jiraan myelofibrosis aasaasiga ah.Daawada hadda waxaa laga heli karaa in ka badan 50 waddan oo adduunka ah.